title: Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.
abstract: The purpose of this study was to examine the effects of a new potent peptidoleukotriene receptor antagonist, SK&F 104353, in splanchnic artery occlusion shock. SK&F 104353 was administered as a 1 mg/kg initial bolus followed by an infusion of 3 mg/kg per h for the entire 2 h post-reperfusion observation period. In a group of conscious rats, this dose of SK&F 104353 shifted the LTD4 dose response curve rightward 10-fold, indicating effective antagonism of peptidoleukotriene responses in the rat. Anesthetized rats subjected to splanchnic artery occlusion shock survived an average of only 98 +/- 8 min whereas all animals receiving SK&F 104353 survived the 2 h reperfusion period (P less than 0.02 from vehicle). Therefore, the survival rate of the splanchnic artery occlusion shock group of rats receiving SK&F 104353 was improved to 100% compared with 50% survival for the vehicle-treated splanchnic artery occlusion shock group (P less than 0.025). In the splanchnic artery occlusion shock + SK&F 104353 group the increase in the plasma activities of the lysosomal hydrolase, cathepsin D, and the cardiotoxic peptide, myocardial depressant factor, were significantly attenuated in comparison to the splanchnic artery occlusion shock + vehicle group (P less than 0.025). These data indicate that the peptidoleukotriene receptor antagonist, SK&F 104353 is beneficial in splanchnic artery occlusion shock, and furthermore suggests that it may be a therapeutically useful agent in bowel ischemic shock.
authors.affiliation: Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
authors.forename: P H
authors.initials: PH
authors.lastname: Lento
authors.forename: K
authors.initials: K
authors.lastname: Saukkonen
authors.forename: N
authors.initials: N
authors.lastname: Aoki
authors.forename: A M
authors.initials: AM
authors.lastname: Lefer
authors.forename: M J
authors.initials: MJ
authors.lastname: Slivjak
authors.forename: E F
authors.initials: EF
authors.lastname: Smith
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003998:Dicarboxylic Acids / Q000097:blood / Q000494:pharmacology*; D008247:Lysosomes / Q000187:drug effects; D008297:Male; D008638:Mesenteric Arteries / Q000503:physiopathology; D008641:Mesenteric Vascular Occlusion / Q000150:complications / Q000503:physiopathology*; D009201:Myocardial Depressant Factor / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D011971:Receptors, Immunologic / Q000187:drug effects*; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012769:Shock / Q000209:etiology / Q000503:physiopathology*; D013997:Time Factors
chemical_list: D003998:Dicarboxylic Acids; D009201:Myocardial Depressant Factor; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; C052393:pobilukast